Table 1 Training cohort clinical characteristics.
N (%) | Median (range) | |
|---|---|---|
Age (years) | 68 (28–83.7) | |
Sex | ||
Male | 7 (44) | |
Female | 9 (56) | |
Drug received | ||
Nivolumab | 4 (25) | |
Pembrolizumab | 12 (75) | |
Stage | ||
Unresectable stage III | 2 (12) | |
M1a | 6 (38) | |
M1b | 1 (6) | |
M1c | 7 (44) | |
Lactic dehydrogenase (U/L) | 287 (51–822) | |